• Je něco špatně v tomto záznamu ?

Genetic validation of a TSC2 immunohistochemistry assay in TSC/mTOR-pathway altered renal tumors

A. Akbari, CR. Villanueva, O. Hes, SR. Williamson, S. Kandukuri, S. Sharma, A. Aditi, K. Pivovarcikova, P. Argani, SK. Mohanty, K. Asrani, TL. Lotan

. 2024 ; 154 (-) : 105693. [pub] 20241119

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010583

Pathogenic mutations in the genes associated with tuberous sclerosis complex (TSC)/mTOR pathway are linked to histologically diverse renal cell neoplasms, including eosinophilic solid and cystic renal cell carcinoma (ESC RCC), low grade oncocytic tumor (LOT), eosinophilic vacuolated tumor (EVT), and xanthomatous giant cell renal cell carcinoma (XGC RCC). Here, we validate a TSC2 immunohistochemistry (IHC) assay by comparison to genomic data in these neoplasms. Automated TSC2 IHC was performed on formalin-fixed paraffin embedded (FFPE) tissues from 38 genetically-confirmed TSC/mTOR-associated renal tumors (6 ESCs, 16 EVTs, 13 LOTs, 2 XGC and 1 clear cell RCC) and visually scored in a semi-dichotomous fashion compared to internal control tissue. The positive predictive value (PPV) of TSC2 protein loss for underlying pathogenic mutation in TSC2 was 92% (11/12), while the negative predictive value (NPV) of intact TSC2 by IHC for lack of underlying pathogenic mutation in TSC2 was 81% (21/26). Intact TSC2 by IHC was 95% (21/22) specific for absence of underlying pathogenic TSC2 mutation. All the cases lacking TSC2 mutation with intact TSC2 protein had an underlying mutation in TSC1, MTOR or PIK3CA. Loss of TSC2 was 77% (10/13) sensitive for underlying TSC2 truncation mutations and 33% (1/3) sensitive for underlying TSC2 missense mutations. Overall, 73% (8/11) tumors with TSC2 IHC loss and underlying pathogenic alterations in TSC2 showed heterogeneous protein loss, with rare interspersed positively staining tumor cells. These data support TSC2 IHC as a potentially useful assay for the diagnostic workup of renal tumors suspected to belong to the TSC/mTOR-associated subgroups.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010583
003      
CZ-PrNML
005      
20250429134631.0
007      
ta
008      
250415e20241119xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.humpath.2024.105693 $2 doi
035    __
$a (PubMed)39571694
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Akbari, Amir $u Department of Pathology, Johns Hopkins School of Medicine, USA; Department of Pathology, University of Southern California Keck School of Medicine, USA. Electronic address: amir.akbari@med.usc.edu
245    10
$a Genetic validation of a TSC2 immunohistochemistry assay in TSC/mTOR-pathway altered renal tumors / $c A. Akbari, CR. Villanueva, O. Hes, SR. Williamson, S. Kandukuri, S. Sharma, A. Aditi, K. Pivovarcikova, P. Argani, SK. Mohanty, K. Asrani, TL. Lotan
520    9_
$a Pathogenic mutations in the genes associated with tuberous sclerosis complex (TSC)/mTOR pathway are linked to histologically diverse renal cell neoplasms, including eosinophilic solid and cystic renal cell carcinoma (ESC RCC), low grade oncocytic tumor (LOT), eosinophilic vacuolated tumor (EVT), and xanthomatous giant cell renal cell carcinoma (XGC RCC). Here, we validate a TSC2 immunohistochemistry (IHC) assay by comparison to genomic data in these neoplasms. Automated TSC2 IHC was performed on formalin-fixed paraffin embedded (FFPE) tissues from 38 genetically-confirmed TSC/mTOR-associated renal tumors (6 ESCs, 16 EVTs, 13 LOTs, 2 XGC and 1 clear cell RCC) and visually scored in a semi-dichotomous fashion compared to internal control tissue. The positive predictive value (PPV) of TSC2 protein loss for underlying pathogenic mutation in TSC2 was 92% (11/12), while the negative predictive value (NPV) of intact TSC2 by IHC for lack of underlying pathogenic mutation in TSC2 was 81% (21/26). Intact TSC2 by IHC was 95% (21/22) specific for absence of underlying pathogenic TSC2 mutation. All the cases lacking TSC2 mutation with intact TSC2 protein had an underlying mutation in TSC1, MTOR or PIK3CA. Loss of TSC2 was 77% (10/13) sensitive for underlying TSC2 truncation mutations and 33% (1/3) sensitive for underlying TSC2 missense mutations. Overall, 73% (8/11) tumors with TSC2 IHC loss and underlying pathogenic alterations in TSC2 showed heterogeneous protein loss, with rare interspersed positively staining tumor cells. These data support TSC2 IHC as a potentially useful assay for the diagnostic workup of renal tumors suspected to belong to the TSC/mTOR-associated subgroups.
650    _2
$a lidé $7 D006801
650    12
$a tuberin $x genetika $7 D000077005
650    12
$a nádory ledvin $x genetika $x patologie $7 D007680
650    12
$a TOR serin-threoninkinasy $x metabolismus $7 D058570
650    12
$a imunohistochemie $7 D007150
650    12
$a karcinom z renálních buněk $x genetika $x patologie $7 D002292
650    12
$a nádorové biomarkery $x genetika $x analýza $7 D014408
650    12
$a nádorové supresorové proteiny $x analýza $x genetika $7 D025521
650    _2
$a mutace $7 D009154
650    _2
$a signální transdukce $7 D015398
650    _2
$a tuberózní skleróza $x genetika $x patologie $x diagnóza $7 D014402
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a mužské pohlaví $7 D008297
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
700    1_
$a Villanueva, Clarence Rachel $u Department of Pathology, Johns Hopkins School of Medicine, USA
700    1_
$a Hes, Ondrej $u Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Williamson, Sean R $u Department of Pathology, Cleveland Clinic, USA
700    1_
$a Kandukuri, Shivani $u Department of Pathology, University of Southern California Keck School of Medicine, USA
700    1_
$a Sharma, Shivani $u CORE Reference Laboratory, Gurgaon, Haryana, India
700    1_
$a Aditi, Aggarwal $u CORE Reference Laboratory, Gurgaon, Haryana, India
700    1_
$a Pivovarcikova, Kristyna $u Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Argani, Pedram $u Department of Pathology, Johns Hopkins School of Medicine, USA
700    1_
$a Mohanty, Sambit K $u Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, OR, India
700    1_
$a Asrani, Kaushal $u Department of Pathology, Johns Hopkins School of Medicine, USA. Electronic address: kasrani1@jhmi.edu
700    1_
$a Lotan, Tamara L $u Department of Pathology, Johns Hopkins School of Medicine, USA; Department of Urology, Johns Hopkins School of Medicine, USA; Department of Oncology, Johns Hopkins School of Medicine, USA. Electronic address: tlotan1@jhmi.edu
773    0_
$w MED00002080 $t Human pathology $x 1532-8392 $g Roč. 154 (20241119), s. 105693
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39571694 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134626 $b ABA008
999    __
$a ok $b bmc $g 2311763 $s 1247664
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 154 $c - $d 105693 $e 20241119 $i 1532-8392 $m Human pathology $n Hum Pathol $x MED00002080
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace